VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for ...
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...
Keep the news in the Wayback Machine. Sign Fight for the Future's letter. Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results